ClinicalTrials.gg
CompletedNCT03863080Updated Dec 20, 2023Results posted

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

A Phase 2 interventional study of RVT-1401 and Placebo in Myasthenia Gravis, sponsored by Immunovant Sciences GmbH. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
82nd of 108
17 · median 56
Started
2019
with 13 others
Phase 2
26 of 144
5 open now
Registered
41st of 144
by date
Lead sponsor
3 of 144
Immunovant Sciences GmbH

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 82nd largest by enrollment of the 108 interventional ones that give a count, is one of 14 that started in 2019, is one of 26 in phase 2, and was the 41st registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

Keywords

  • IMVT-1401
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age.
  2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator.
  3. QMG score ≥12 at Screening and Baseline.

Other, more specific inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.
  2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.
  3. Thymectomy performed \< 12 months prior to screening.
  4. Total IgG level \<6 g/L (at screening).
  5. \<1500 cells/mm3(at screening).

Other, more specific exclusion criteria are defined in the protocol

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Regimen A

    RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)

    Drug: RVT-1401

  • Experimental
    Regimen B

    RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)

    Drug: RVT-1401

  • Placebo comparator
    Placebo

    Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)

    Drug: RVT-1401 · Drug: Placebo

Interventions

  • Subcutaneous administration of RVT-1401

  • DrugPlacebo

    Subcutaneous administration of Placebo

06

What researchers measure

Primary outcomes

  1. Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

    Time frame: Up to Week 18

  2. Open-Label Extension Period: Number of Participants Reporting AEs and SAEs

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

    Time frame: Up to Week 18

  3. Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.

    Time frame: Up to Week 7

  4. Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs including SBP, DBP, pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.

    Time frame: Up to Week 18

  5. Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.

    Time frame: Up to Week 7

  6. Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.

    Time frame: Up to Week 18

  7. Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)

    Twelve-lead ECG was performed after 5 minutes of rest in the supine position.

    Time frame: Up to Week 7

  8. Open-label Extension Period: Number of Participants With Clinically Significant Changes in ECG

    Twelve-lead ECG was performed after 5 minutes of rest in the supine position.

    Time frame: Up to Week 18

  9. Double-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG)

    Serum samples were collected for the analysis of total immunoglobulin G. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

    Time frame: Baseline (Day 1) and Up to Week 7

  10. Double-blind Treatment Period: Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4

    Serum samples were collected for the analysis of IgG 1, 2, 3 and 4 levels. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

    Time frame: Baseline (Day 1) and Up to Week 7

  11. Double-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7

    Serum samples were collected for the analysis of Anti-AChR-IgG. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

    Time frame: Baseline (Day 1) and Week 7

Secondary outcomes

  1. Double-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401

    Blood samples were collected for the analysis of Pharmacokinetic parameter AUC (0-168h).

    Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8

  2. Open-label Extension Period: AUC0-168h of RVT-1401

    Pharmacokinetic parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.

    Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14

  3. Double-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401

    Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.

    Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8

  4. Open-label Extension Period: Cmax of RVT-1401

    Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.

    Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14

  5. Double-Blind Treatment Period: Trough Concentrations (Ctrough) of RVT-1401

    Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.

    Time frame: Pre-dose

  6. Open-label Extension Period: Ctrough of RVT-1401

    Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.

    Time frame: Pre-dose

  7. Double-blind Treatment Period: Change From Baseline in the Quantitative Myasthenia Gravis Score (QMG) Score

    The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36) and Week 7

  8. Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the QMG Score From Baseline

    The response is defined as improvement from Baseline on the QMG score by =\> 3 points. The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1) to Week 7

  9. Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Score

    The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7

  10. Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the MG-ADL Score

    The response was defined as improvement (decrease) from Baseline on the MG-ADL score by =\> 2 points. The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.

    Time frame: Baseline (Day 1) to Week 7

  11. Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Composite Score (MGC) Score

    The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7

  12. Double-Blind Treatment Period: Percentage of Participants With an Improvement on the MGC Score

    The response was defined as improvement (decrease) from Baseline on the MGC score by =\> 3 points. The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.

    Time frame: Baseline (Day 1) to Week 7

  13. Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Quality of Life 15 Revised Score (MG-QOL 15r) Score

    The MG-QOL15r is a participant-reported questionnaire designed to assess how a participant's Myasthenia Gravis affects different aspects related to their quality of life. The scale includes 15 items that are graded on a scale of 0 to2; the total across is the sum of all 15 items and represents the MG-QOL15r score. The range of the MG-QOL15r score is 0 - 30. Higher scores indicate worse outcomes. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1) and at Week 4 and Week 7

  14. Double-Blind Treatment Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies

    The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of anti-drug antibody (ADA) to assess specificity of screened positive samples.

    Time frame: Up to Week 7

  15. Open-Label Extension Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies

    The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of ADA to assess specificity of screened positive samples.

    Time frame: Up to Week 18

07

Results

Posted Dec 20, 2023

Participant flow

This was a Phase 2a, randomized, double-blind (DB), placebo-controlled study with an Open-Label Extension (OLE) that was designed to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RVT-1401 versus placebo in acetylcholine receptor (AChR) antibody positive myasthenia gravis (MG) participants.

Double-Blind Treatment Period (6 Weeks)
Participant flow — Double-Blind Treatment Period (6 Weeks)
MilestoneDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekOpen-label Extension Period: RVT-1401 340 mg Biweekly
Started6560
Completed6550
Not completed0010
Withdrew: Adverse event0010
Open Label Extension Period (12 Weeks)
Participant flow — Open Label Extension Period (12 Weeks)
MilestoneDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekOpen-label Extension Period: RVT-1401 340 mg Biweekly
Started00015
Completed0009
Not completed0006
Withdrew: Withdrawal by subject0003
Withdrew: Adverse event0003

Outcome measures

PrimaryDouble-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Any AE545
Any SAE001
PrimaryOpen-Label Extension Period: Number of Participants Reporting AEs and SAEs

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Open-Label Extension Period: Number of Participants Reporting AEs and SAEs
ParticipantsOpen-Label Extension Period: RVT-1401 340 mg Biweekly
Any AE10
Any SAE1
PrimaryDouble-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs

Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.

Time frame:
Up to Week 7
Reported as:
Count of participants · Participants
Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs000
PrimaryOpen-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs

Vital signs including SBP, DBP, pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs000
PrimaryDouble-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.

Time frame:
Up to Week 7
Reported as:
Count of participants · Participants
Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters000
PrimaryOpen-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters000
PrimaryDouble-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)

Twelve-lead ECG was performed after 5 minutes of rest in the supine position.

Time frame:
Up to Week 7
Reported as:
Count of participants · Participants
Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)000
PrimaryOpen-label Extension Period: Number of Participants With Clinically Significant Changes in ECG

Twelve-lead ECG was performed after 5 minutes of rest in the supine position.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Open-label Extension Period: Number of Participants With Clinically Significant Changes in ECG
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Open-label Extension Period: Number of Participants With Clinically Significant Changes in ECG000
PrimaryDouble-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG)

Serum samples were collected for the analysis of total immunoglobulin G. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

Time frame:
Baseline (Day 1) and Up to Week 7
Reported as:
Least squares mean · Percent change
Double-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG)
Percent changeDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG)-3.17 ± 2.97-59.49 ± 3.15-77.66 ± 2.92
Statistical analysis
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 340 mg/Week · ANCOVA · p = <0.0001 · Least square mean difference: -56.33Treatment comparison between Placebo and RVT-1401 340 mg/week of Total IgG levels has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 680 mg/Week · ANCOVA · p = <0.0001 · Least square mean difference: -74.49Treatment comparison between Placebo and RVT-1401 680 mg/week of Total IgG levels has been presented.
PrimaryDouble-blind Treatment Period: Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4

Serum samples were collected for the analysis of IgG 1, 2, 3 and 4 levels. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

Time frame:
Baseline (Day 1) and Up to Week 7
Reported as:
Least squares mean · Percent change
Double-blind Treatment Period: Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4
Percent changeDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
IgG1-3.3 ± 3.67-65.9 ± 4.02-76.3 ± 3.98
IgG2-2.2 ± 5.35-54.7 ± 5.65-63.6 ± 5.60
IgG3-2.1 ± 4.69-68.2 ± 5.05-82.9 ± 5.12
IgG4-3.1 ± 5.68-48.0 ± 6.08-64.7 ± 6.10
Statistical analysis
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 340 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -62.7Treatment comparison between Placebo and RVT-1401 340 mg/week of IgG 1 subclass has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 680 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -73.0Treatment comparison between Placebo and RVT-1401 680 mg/week of IgG 1 subclass has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 340 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -52.5Treatment comparison between Placebo and RVT-1401 340 mg/week of IgG 2 subclass has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 680 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -61.4Treatment comparison between Placebo and RVT-1401 680 mg/week of IgG 2 subclass has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 340 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -66.1Treatment comparison between Placebo and RVT-1401 340 mg/week of IgG 3 subclass has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 680 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -80.8Treatment comparison between Placebo and RVT-1401 680 mg/week of IgG 3 subclass has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 340 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -44.9Treatment comparison between Placebo and RVT-1401 340 mg/week of IgG 4 subclass has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 680 mg/Week · ANCOVA · p = <0.001 · Least square mean difference: -61.6Treatment comparison between Placebo and RVT-1401 680 mg/week of IgG 4 subclass has been presented.
PrimaryDouble-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7

Serum samples were collected for the analysis of Anti-AChR-IgG. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

Time frame:
Baseline (Day 1) and Week 7
Reported as:
Least squares mean · Percent change
Double-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7
Percent changeDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 715.92 ± 12.41-46.66 ± 13.64-85.28 ± 12.27
Statistical analysis
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 340 mg/Week · ANCOVA · p = 0.0009 · Least square mean difference: -62.58Treatment comparison between Placebo and RVT-1401 340 mg/week of Anti-AChR-IgG has been presented.
  • Double-blind Treatment Period: Placebo vs Double-blind Treatment Period: RVT-1401 680 mg/Week · ANCOVA · p = <0.0001 · Least square mean difference: -101.20Treatment comparison between Placebo and RVT-1401 680 mg/week of Anti-AChR-IgG has been presented.
SecondaryDouble-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401

Blood samples were collected for the analysis of Pharmacokinetic parameter AUC (0-168h).

Time frame:
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Reported as:
Geometric mean · Hours*microgram per milliliter
Double-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401
Hours*microgram per milliliterDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401NA ± NANA ± NA
SecondaryOpen-label Extension Period: AUC0-168h of RVT-1401

Pharmacokinetic parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.

Time frame:
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14
Reported as:
Geometric mean · Hours*microgram per milliliter
Open-label Extension Period: AUC0-168h of RVT-1401
Hours*microgram per milliliterDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Open-label Extension Period: AUC0-168h of RVT-1401NA ± NANA ± NA
SecondaryDouble-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401

Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.

Time frame:
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Reported as:
Geometric mean · micrograms per milliliter
Double-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401
micrograms per milliliterDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401NA ± NANA ± NA
SecondaryOpen-label Extension Period: Cmax of RVT-1401

Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.

Time frame:
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14
Reported as:
Geometric mean · Micrograms per milliliter
Open-label Extension Period: Cmax of RVT-1401
Micrograms per milliliterDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Open-label Extension Period: Cmax of RVT-1401NA ± NANA ± NA
SecondaryDouble-Blind Treatment Period: Trough Concentrations (Ctrough) of RVT-1401

Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.

Time frame:
Pre-dose
Reported as:
Mean · Milligrams per liter
Double-Blind Treatment Period: Trough Concentrations (Ctrough) of RVT-1401
Milligrams per literDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Trough Concentrations (Ctrough) of RVT-1401NA ± NANA ± NA
SecondaryOpen-label Extension Period: Ctrough of RVT-1401

Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.

Time frame:
Pre-dose
Reported as:
Mean · Milligrams per liter
Open-label Extension Period: Ctrough of RVT-1401
Milligrams per literDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Open-label Extension Period: Ctrough of RVT-1401NA ± NANA ± NA
SecondaryDouble-blind Treatment Period: Change From Baseline in the Quantitative Myasthenia Gravis Score (QMG) Score

The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36) and Week 7
Reported as:
Mean · Scores on a scale
Double-blind Treatment Period: Change From Baseline in the Quantitative Myasthenia Gravis Score (QMG) Score
Scores on a scaleDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Week 2, n=6,5,6-3.3 ± 2.16-2.8 ± 5.36-1.7 ± 3.14
Week 3, n=6,5,6-2.5 ± 2.74-4.6 ± 7.70-2.5 ± 2.95
Week 4, n=6,5,5-2.7 ± 2.73-3.6 ± 6.43-3.6 ± 4.16
Week 5, n=6,5,5-2.7 ± 2.73-3.2 ± 6.80-3.2 ± 3.70
Week 6 (Day 36), n=6,5,5-3.0 ± 3.22-4.0 ± 6.75-4.4 ± 3.71
Week 7, n=5,5,5-1.8 ± 3.27-4.0 ± 6.82-3.8 ± 4.76
SecondaryDouble-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the QMG Score From Baseline

The response is defined as improvement from Baseline on the QMG score by =\> 3 points. The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1) to Week 7
Reported as:
Number · Percentage of participants
Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the QMG Score From Baseline
Percentage of participantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the QMG Score From Baseline20.040.060.0
SecondaryDouble-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Score

The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7
Reported as:
Mean · Scores on a scale
Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Score
Scores on a scaleDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Week 2-1.7 ± 2.34-3.2 ± 6.61-0.7 ± 0.82
Week 3-0.8 ± 2.04-3.8 ± 5.97-1.7 ± 1.97
Week 4-0.8 ± 2.64-3.2 ± 6.38-2.0 ± 2.35
Week 5-1.5 ± 3.02-3.2 ± 6.65-2.0 ± 2.35
Week 6 (Day 36)-1.2 ± 3.19-5.2 ± 7.09-3.4 ± 3.36
Week 7-0.2 ± 2.71-4.4 ± 7.06-3.2 ± 3.11
SecondaryDouble-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the MG-ADL Score

The response was defined as improvement (decrease) from Baseline on the MG-ADL score by =\> 2 points. The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.

Time frame:
Baseline (Day 1) to Week 7
Reported as:
Number · Percentage of participants
Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the MG-ADL Score
Percentage of participantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the MG-ADL Score33.360.060.0
SecondaryDouble-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Composite Score (MGC) Score

The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7
Reported as:
Mean · Scores on a scale
Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Composite Score (MGC) Score
Scores on a scaleDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Week 2-2.3 ± 2.94-7.0 ± 9.27-3.0 ± 3.10
Week 3-1.3 ± 5.20-8.8 ± 9.98-2.3 ± 2.88
Week 4-2.0 ± 8.10-7.2 ± 10.40-4.0 ± 6.60
Week 5-4.3 ± 7.50-7.0 ± 10.07-2.8 ± 4.97
Week 6 (Day 36)-2.5 ± 8.04-10.4 ± 9.32-6.6 ± 5.13
Week 7-0.8 ± 7.33-9.0 ± 10.12-7.0 ± 5.34
SecondaryDouble-Blind Treatment Period: Percentage of Participants With an Improvement on the MGC Score

The response was defined as improvement (decrease) from Baseline on the MGC score by =\> 3 points. The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.

Time frame:
Baseline (Day 1) to Week 7
Reported as:
Number · Percentage of participants
Double-Blind Treatment Period: Percentage of Participants With an Improvement on the MGC Score
Percentage of participantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Percentage of Participants With an Improvement on the MGC Score40.060.060.0
SecondaryDouble-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Quality of Life 15 Revised Score (MG-QOL 15r) Score

The MG-QOL15r is a participant-reported questionnaire designed to assess how a participant's Myasthenia Gravis affects different aspects related to their quality of life. The scale includes 15 items that are graded on a scale of 0 to2; the total across is the sum of all 15 items and represents the MG-QOL15r score. The range of the MG-QOL15r score is 0 - 30. Higher scores indicate worse outcomes. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1) and at Week 4 and Week 7
Reported as:
Mean · Scores on a scale
Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Quality of Life 15 Revised Score (MG-QOL 15r) Score
Scores on a scaleDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Week 4-3.5 ± 3.83-6.0 ± 9.771.6 ± 5.03
Week 7-2.3 ± 3.93-6.6 ± 10.552.0 ± 4.42
SecondaryDouble-Blind Treatment Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies

The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of anti-drug antibody (ADA) to assess specificity of screened positive samples.

Time frame:
Up to Week 7
Reported as:
Count of participants · Participants
Double-Blind Treatment Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Double-Blind Treatment Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies211
SecondaryOpen-Label Extension Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies

The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of ADA to assess specificity of screened positive samples.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Open-Label Extension Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies
ParticipantsDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/Week
Open-Label Extension Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies100

Adverse events

Collected over From Baseline and Up to Week 18. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Treatment Period: Placebo0/6 (0%)0/6 (0%)5/6 (83.3%)
Double-blind Treatment Period: RVT-1401 340 mg/Week0/5 (0%)0/5 (0%)4/5 (80%)
Double-blind Treatment Period: RVT-1401 680 mg/Week0/6 (0%)1/6 (16.7%)5/6 (83.3%)
Open-label Extension Period: RVT-1401 340 mg Biweekly0/15 (0%)1/15 (6.7%)10/15 (66.7%)
Most frequent serious events
Most frequent serious events
EventDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekOpen-label Extension Period: RVT-1401 340 mg Biweekly
Herpes simplexInfections and infestations0/60/51/60/15
Myasthenia gravisNervous system disorders0/60/50/61/15
Most frequent other events
Showing 10 of 37
Most frequent other events
EventDouble-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekOpen-label Extension Period: RVT-1401 340 mg Biweekly
HeadacheNervous system disorders3/61/50/62/15
Injection site erythemaGeneral disorders1/62/51/62/15
Muscle spasmsMusculoskeletal and connective tissue disorders2/61/50/61/15
DizzinessNervous system disorders1/60/52/60/15
Injection site bruisingGeneral disorders0/61/50/60/15
Injection site swellingGeneral disorders1/61/50/61/15
Upper respiratory tract infectionInfections and infestations0/61/50/60/15
Urinary tract infectionInfections and infestations0/61/50/60/15
Red blood cell count increasedInvestigations0/61/50/60/15
White blood cells urine positiveInvestigations0/61/50/60/15

Baseline characteristics

Safety Analysis Set (SAF) comprised of all participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(Years)Double-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekTotal
Mean41.0 ± 15.4056.8 ± 22.1770.8 ± 14.2256.2 ± 20.67
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekTotal
Female4217
Male23510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekTotal
Hispanic or Latino0000
Not Hispanic or Latino65516
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-blind Treatment Period: PlaceboDouble-blind Treatment Period: RVT-1401 340 mg/WeekDouble-blind Treatment Period: RVT-1401 680 mg/WeekTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White65617
More than one race0000
Unknown or Not Reported0000
08

Study locations

20 sites
  • IMC/Diagnostic and Medical Clinic
    Mobile, Alabama 36604, United States
  • Phoenix Neurological Associates
    Phoenix, Arizona 85018, United States
  • The Neurology Center of Southern California
    Carlsbad, California 92011, United States
  • UC Irvine - MDA ALS and Neuromuscular Center
    Orange, California 92868, United States
  • Care Access Research
    Pasadena, California 91101, United States
  • CSNA
    Colorado Springs, Colorado 80907, United States
  • Yale School of Medicine Department of Neurology
    New Haven, Connecticut 06510, United States
  • Neurological Services of Orlando
    Orlando, Florida 32806, United States
  • Rare Disease Research
    Atlanta, Georgia 30318, United States
  • University of Minnesota - Department of Neurology
    Minneapolis, Minnesota 55455, United States
  • Dent Institute
    Amherst, New York 14221, United States
  • University of Buffalo
    Buffalo, New York 14260-1660, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Allegheny Neurological Associates
    Pittsburgh, Pennsylvania 15212, United States
  • UTSW James W. Aston Ambulatory Care Center - Neurology Clinic
    Dallas, Texas 75390, United States
  • University of Alberta Hospitals - Division of Pulmonary Medicine
    Edmonton, Alberta T6G 2G3, Canada
  • London Health Sciences Centre
    London, Ontario N6G 2V4, Canada
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1Y 4E9, Canada
  • University Health Network Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Oct 2020, 16 months.

Results were first posted in Dec 2023, 3 years 2 months after primary completion. A results delay was requested in Oct 2021.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Mar 5, 2019
StartActual
May 21, 2019
Primary completionActual
Oct 7, 2020
CompletionActual
Dec 21, 2020
Results delay requested
Oct 6, 2021
Results first posted
Dec 20, 2023
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03863080
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Mar 5, 2019
Start date
May 21, 2019
Primary completion
Oct 7, 2020
Completion
Dec 21, 2020
Results posted
Dec 20, 2023
Last update
Dec 20, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion